FDA asks Vivus to check on Qnexa's risk of birth defects

01/23/2011 | Wall Street Journal, The

The FDA has requested that Vivus evaluate the feasibility of reviewing databases to find out whether topiramate, an active ingredient in the company's weight-loss pill Qnexa, increases the risk of oral cleft in children whose mothers took the medicine during pregnancy. Vivus said it thinks the agency's request is based on published cases of birth defects linked to topiramate, which is used for migraine and epilepsy, in North America and the U.K.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA